StockpollyBeta
Get App
Popularity #4,315Earnings today
IXHL · NASDAQ · Biotechnology

Incannex Healthcare (IXHL)

Develops combination medicines and a psilocybin-assisted therapy candidate for chronic diseases.

$3.47
vs last close+0.07 (+2.21%)

In millions of USD, except per-share figures

In millionsQ3 FY23Mar 2023Q4 FY23Jun 2023Q2 FY24Sep 2023Q1 FY24Sep 2023Q4 FY24Mar 2024Q3 FY24Mar 2024Q2 FY25Sep 2024Q1 FY25Sep 2024Q3 FY25Mar 2025Q4 FY25Jun 2025Q2 FY26Dec 2025Q3 FY26Mar 2026
Revenue000000——0000
Cost of revenue000000000000
Gross profit000000——0—00
512881111——51974
Research & development244455——3920
354466——21054
Selling & marketing030000000000
General & administrative324466——21054
Other expenses030000000000
Operating income−5−12−8−8−11−11——−5−19−7−4
007722——1−2600
Interest income000000——0000
Interest expense000000000000
Other non-operating income00−6−6−2−2——−1000
Income before tax−5−12−1−1−9−9−8−8−4−45−7−4
Net income from continuing operations−571−1−1−9−9−8−8−4−36−7−4
Net income−571−1−1−9−9−8−8−4−36−7−4
EPS, basic−$0.66−$0.89−$0.24−$0.24−$1.14−$1.14−$0.87−$0.87−$0.60−$0.69−$0.60−$0.35
EPS, diluted−$0.66−$0.89−$0.24−$0.24−$1.14−$1.14−$0.87−$0.87−$0.60−$0.69−$0.60−$0.35
Weighted average shares, basic555555667101212
Weighted average shares, diluted555555667101212
EBITDA−6−9−1−1−9−9——−4−39−6−4
Depreciation & amortization000000——0000
EBIT−6−9−1−1−9−9——−4−39−7−4